Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform

1d ago, source:

Cidara Therapeutics, Inc. secures funding and focuses on oncology platform after passing rezafungin rights to Mundipharma.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

4d ago, source:

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 ...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

5d ago, source:

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary ...

Why Cidara Therapeutics (CDTX) Stock Is Falling

on MSN ago, source:

Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading lower by 24.4% to $0.52 Monday afternoon. The company announced a ...

Cidara regains rights to flu med after Janssen makes good on promise to divest

4d ago, source: FierceBiotech

Cidara Therapeutics already knew that Janssen planned to hand off its obligations to their flu prophylaxis candidate to ...

Cidara Therapeutics Inc (NASDAQ: CDTX) Stock: Bulls Need To See This

12d ago, source:

A look at today’s price movement shows that the recent level at last check reads $0.82. Taking into account the 52-week price ...

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

2d ago, source: Stockhouse

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) ...

Cidara Therapeutics Inc (CDTX) Shares Plummet Below 1-Year High

6d ago, source: newsheater

The stock of Cidara Therapeutics Inc (CDTX) has seen a -37.13% decrease in the past week, with a -35.44% drop in the past month, and a -27.47% fall in the past quarter. The volatility ratio for the ...

Cidara Therapeutics Inc (CDTX): A Technical Analysis

11d ago, source: newsheater

Cidara Therapeutics Inc (NASDAQ: CDTX)’s stock price has dropped by -11.48 in relation to previous closing price of 0.82. Nevertheless, the company has seen a loss of -16.57% in its stock price over ...

Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

2d ago, source:

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies ...

Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

5d ago, source:

Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) ...